stock-detail (ADAP)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/9/2017 06:17 am

Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit

3/27/2017 08:03 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 27, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’ s Chief Executive Officer, ...

Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

3/27/2017 03:03 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, UK, March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune") (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing ...

Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

3/27/2017 03:02 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, UK, March 27, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering ...

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

3/22/2017 02:00 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced ...

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

3/22/2017 01:05 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 ...

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

3/21/2017 11:04 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, 2017-03-22 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer ...

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

3/21/2017 08:05 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 21, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary ...

Adaptimmune Broadens Executive Team

3/15/2017 11:03 am

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment ...

Adaptimmune Broadens Executive Team

3/15/2017 11:03 am

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened ...